Thermo Fisher Scientific Inc. $TMO Shares Purchased by Capital International Investors

Capital International Investors raised its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.6% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 920,143 shares of the medical research company’s stock after purchasing an additional 5,136 shares during the quarter. Capital International Investors’ holdings in Thermo Fisher Scientific were worth $533,179,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of TMO. High Note Wealth LLC raised its stake in Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after buying an additional 29 shares in the last quarter. JPL Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth approximately $28,000. Beacon Financial Strategies CORP acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $29,000. Olistico Wealth LLC acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $29,000. Finally, Core Wealth Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $30,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $472.98 on Monday. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $643.99. The firm has a market capitalization of $175.77 billion, a price-to-earnings ratio of 26.00, a price-to-earnings-growth ratio of 2.09 and a beta of 0.88. The business has a 50 day simple moving average of $479.94 and a 200 day simple moving average of $530.83. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period last year, the company posted $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio is 10.34%.

Insider Activity at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Wall Street Zen cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Morgan Stanley reiterated an “overweight” rating and set a $620.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. Robert W. Baird dropped their price target on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Wolfe Research initiated coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price objective for the company. Finally, Royal Bank Of Canada set a $490.00 price objective on Thermo Fisher Scientific and gave the stock a “sector perform” rating in a report on Thursday, May 14th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $613.67.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.